Novo Nordisk has regained competitive ground in the obesity market with the strong launch of its Wegovy pill, which outperforms Eli Lilly's Foundayo in new prescriptions due to better weight loss results and fewer drug interaction limits. Despite recent setbacks, Novo Nordisk is advancing promising late-stage drug candidates aiming to compete with Eli Lilly's future products by the early 2030s. Both companies are expected to dominate obesity and diabetes markets through at least the mid-2030s, as no other competitors currently offer disruptive innovations in this space.
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
Novo Nordisk's stock has fallen about 28% over the past year, but it remains a Buy due to strong long-term growth prospects and favorable catalysts. The company has outperformed the benchmark with a 41% surge since previous coverage, despite recent r...
Novo Nordisk shares dropped 2.5% after Deutsche Bank's weekly prescription data tracker indicated a continued slowdown in the oral version of its weight-loss drug, Wegovy, in the US. This slowdown is significant because the oral formulation was seen ...
UBS has reiterated its overweight stance on European pharmaceuticals, viewing the sector as a more stable investment than artificial intelligence amid a slowing market. The bank highlights improving earnings, low valuations, and lighter ownership as ...
The weight loss drug market, driven by GLP-1 therapies, is expected to grow to $130-150 billion by 2035. The Amplify Weight Loss Drug & Treatment ETF (THNR) offers investors targeted exposure to this expanding sector, including major pharmaceutical c...
